HDAC9 and inflammatory bowel disease: CMap analysis identified MS.275, a selective histone deacetylase (HDAC) inhibitor known to suppress inflammation and modulate T cell, B cell, and myeloid cell activities across multiple disease settings, as the top therapeutic enhancer for IBD treatment (42).